Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Clinical trial NCT00654875 · COMPLETED

Trial details

NCT number: NCT00654875
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Essential Hypertension

Start date: 2008-03-01
Primary completion: 2008-11-01
Enrollment: 328

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.